Hatchtech Pty Ltd is a specialty pharmaceutical company located in Melbourne, Australia. The Company has developed Xeglyze™ Lotion, a proprietary next generation head lice treatment.
Xeglyze™ is a topical lotion containing an inhibitor of metalloproteinases known to impede a number of physiological processes involved in all stages of the louse lifecycle from egg to adult. A substantial body of scientific data has established its mode of action, and preclinical and clinical studies have evaluated the efficacy and safety of Xeglyze™.
The Company was originally founded through programs that originated at the University of Melbourne in Australia. Hatchtech has a comprehensive patent estate for Xeglyze™ Lotion including granted U.S. and EU patents, and several pending patent applications
In 2015, Hatchtech sold the rights of Xeglyze™ Lotion to Dr Reddy’s Laboratories for commercialization in the territories of the United States, Canada, India, Russia and the CIS, Australia, New Zealand and Venezuela. Hatchtech will retain global rights for non-human applications of Xeglyze™ Lotion and its active ingredient, abametapir, as well as the right to commercialize the product for human use in territories outside of agreement with Dr. Reddy’s.
Aug 03, 2020 Xeglyze FDA Approval
Sep 14, 2015 Commercialisation Deal and NDA Filed
Sep 02, 2014 Hatchtech Announces Successful Phase 3 Results